Maintenance Belantamab Mafodotin (Blenrep®) After B-cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple Myeloma

NCT05117008 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped Low enrollment.

Conditions

Refractory Multiple Myeloma
Relapse Multiple Myeloma

Interventions

DRUG: Belantamab mafodotin

Sponsor

Medical College of Wisconsin